Collin Matthew, Bigley Venetia, McClain Kenneth L, Allen Carl E
Human Dendritic Cell Laboratory, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Texas Children's Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Hematol Oncol Clin North Am. 2015 Oct;29(5):825-38. doi: 10.1016/j.hoc.2015.06.003. Epub 2015 Aug 20.
Langerhans cell histiocytosis (LCH) is heterogeneous disease characterized by common histology of inflammatory lesions containing Langerin(+) (CD207) histiocytes. Emerging data support a model in which MAPK activation in self-renewing hematopoietic progenitors may drive disseminated high-risk disease, whereas MAPK activation in more differentiated committed myeloid populations may induce low-risk LCH. The heterogeneous clinical manifestations with shared histology may represent the final common pathway of an acquired defect of differentiation, initiated at more than one point. Implications of this model include re-definition of LCH as a myeloid neoplasia and re-focusing therapeutic strategies on the cells and lineages of origin.
朗格汉斯细胞组织细胞增多症(LCH)是一种异质性疾病,其特征是炎症性病变具有共同的组织学表现,包含朗格素(+)(CD207)组织细胞。新出现的数据支持一种模型,即自我更新的造血祖细胞中的丝裂原活化蛋白激酶(MAPK)激活可能驱动播散性高危疾病,而在分化程度更高的定向髓系细胞群体中的MAPK激活可能诱发低风险LCH。具有共同组织学表现的异质性临床表现可能代表了在多个点启动的获得性分化缺陷的最终共同途径。该模型的意义包括将LCH重新定义为一种髓系肿瘤,并将治疗策略重新聚焦于起源的细胞和谱系。